VioQuest Pharmaceuticals Inc
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog tha… Read more
VioQuest Pharmaceuticals Inc (VOQP) - Net Assets
Latest net assets as of June 2008: $-5.67 Million USD
Based on the latest financial reports, VioQuest Pharmaceuticals Inc (VOQP) has net assets worth $-5.67 Million USD as of June 2008.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.18 Million) and total liabilities ($6.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.67 Million |
| % of Total Assets | -481.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -643.33% |
| 10-Year Change | -2844.92% |
| Growth Volatility | 143.39 |
VioQuest Pharmaceuticals Inc - Net Assets Trend (1995–2007)
This chart illustrates how VioQuest Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VioQuest Pharmaceuticals Inc (1995–2007)
The table below shows the annual net assets of VioQuest Pharmaceuticals Inc from 1995 to 2007.
| Year | Net Assets | Change |
|---|---|---|
| 2007-12-31 | $-4.48 Million | -257.85% |
| 2006-12-31 | $2.84 Million | -55.19% |
| 2005-12-31 | $6.34 Million | +67.27% |
| 2004-12-31 | $3.79 Million | +359.18% |
| 2003-12-31 | $825.33K | -73.81% |
| 2002-12-31 | $3.15 Million | +6824.70% |
| 2001-12-31 | $-46.86K | -130.98% |
| 2000-12-31 | $151.23K | -19.60% |
| 1999-12-31 | $188.11K | +15.15% |
| 1998-12-31 | $163.37K | +0.54% |
| 1997-12-31 | $162.48K | -30.09% |
| 1996-12-31 | $232.41K | +11.64% |
| 1995-12-31 | $208.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to VioQuest Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3481076900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2007)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $54.62K | % |
| Other Components | $34.89 Million | % |
| Total Equity | $-4.48 Million | 100.00% |
VioQuest Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of VioQuest Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TANTALIZERS PLC
XNSA:TANTALIZER
|
$27.09 |
|
TRIPPLE GEE AND COMPANY PLC
XNSA:TRIPPLEG
|
$27.14 |
|
US Solar Fund PLC
LSE:USFP
|
$27.33 |
|
American Graphite Technologies Inc
PINK:AGIN
|
$27.48 |
|
Regnum Corp
PINK:RGMP
|
$26.99 |
|
MUTUAL BENEFITS ASSURANCE PLC
XNSA:MBENEFIT
|
$26.72 |
|
REAL ESTATE INVESTMENTS ZAMBIA PLC
LUSE:REIZUSD
|
$26.42 |
|
Manila Bulletin Publishing Corp
PSE:MB
|
$26.35 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VioQuest Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2006 to 2007, total equity changed from 2,840,759 to -4,484,268, a change of -7,325,027 (-257.9%).
- Net loss of 10,891,741 reduced equity.
- Other factors increased equity by 3,566,714.
Equity Change Factors (2006 to 2007)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.89 Million | -242.89% |
| Other Changes | $3.57 Million | +79.54% |
| Total Change | $- | -257.85% |
Book Value vs Market Value Analysis
This analysis compares VioQuest Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $11.02 | $0.00 | x |
| 1996-12-31 | $13.37 | $0.00 | x |
| 1997-12-31 | $9.26 | $0.00 | x |
| 1998-12-31 | $8.36 | $0.00 | x |
| 1999-12-31 | $8.61 | $0.00 | x |
| 2000-12-31 | $8.62 | $0.00 | x |
| 2001-12-31 | $-2.52 | $0.00 | x |
| 2002-12-31 | $12.43 | $0.00 | x |
| 2003-12-31 | $0.66 | $0.00 | x |
| 2004-12-31 | $2.22 | $0.00 | x |
| 2005-12-31 | $2.88 | $0.00 | x |
| 2006-12-31 | $0.71 | $0.00 | x |
| 2007-12-31 | $-0.96 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VioQuest Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-75.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 0.42% | 0.13% | 1.79x | 1.85x | $-19.94K |
| 1996 | -7.79% | -2.85% | 1.57x | 1.73x | $-41.35K |
| 1997 | -43.04% | -14.37% | 1.61x | 1.87x | $-86.18K |
| 1998 | 1.08% | 0.31% | 1.92x | 1.83x | $-14.57K |
| 1999 | 23.26% | 6.91% | 1.83x | 1.84x | $24.94K |
| 2000 | -113.14% | -39.97% | 1.38x | 2.05x | $-186.23K |
| 2001 | 0.00% | -45.00% | 2.10x | 0.00x | $-193.40K |
| 2002 | -1.65% | -156.59% | 0.01x | 1.04x | $-366.99K |
| 2003 | -244.56% | -301.69% | 0.42x | 1.92x | $-2.10 Million |
| 2004 | -106.17% | -270.92% | 0.30x | 1.29x | $-4.40 Million |
| 2005 | -202.47% | -337.34% | 0.45x | 1.32x | $-13.47 Million |
| 2006 | -291.16% | 0.00% | 0.00x | 2.05x | $-8.56 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.44 Million |
Industry Comparison
This section compares VioQuest Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VioQuest Pharmaceuticals Inc (VOQP) | $-5.67 Million | 0.42% | N/A | $27.05 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |